Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected].
The abundant flavonoid aglycone, naringenin, which is responsible for the bitter taste in grapefruits, has been shown to possess hypolipidemic and anti-inflammatory effects both in vitro and in vivo. Recently, our group demonstrated that naringenin inhibits hepatitis C virus (HCV) production, while...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-04-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0018033&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725769208561664 |
|---|---|
| author | Maria Shulman Merav Cohen Alejandro Soto-Gutierrez Hiroshi Yagi Hongyun Wang Jonathan Goldwasser Carolyn W Lee-Parsons Ofra Benny-Ratsaby Martin L Yarmush Yaakov Nahmias |
| author_facet | Maria Shulman Merav Cohen Alejandro Soto-Gutierrez Hiroshi Yagi Hongyun Wang Jonathan Goldwasser Carolyn W Lee-Parsons Ofra Benny-Ratsaby Martin L Yarmush Yaakov Nahmias |
| author_sort | Maria Shulman |
| collection | DOAJ |
| description | The abundant flavonoid aglycone, naringenin, which is responsible for the bitter taste in grapefruits, has been shown to possess hypolipidemic and anti-inflammatory effects both in vitro and in vivo. Recently, our group demonstrated that naringenin inhibits hepatitis C virus (HCV) production, while others demonstrated its potential in the treatment of hyperlipidemia and diabetes. However, naringenin suffers from low oral bioavailability critically limiting its clinical potential. In this study, we demonstrate that the solubility of naringenin is enhanced by complexation with β-cyclodextrin, an FDA approved excipient. Hydroxypropoyl-β-cyclodextrin (HPβCD), specifically, increased the solubility of naringenin by over 400-fold, and its transport across a Caco-2 model of the gut epithelium by 11-fold. Complexation of naringenin with HPβCD increased its plasma concentrations when fed to rats, with AUC values increasing by 7.4-fold and C(max) increasing 14.6-fold. Moreover, when the complex was administered just prior to a meal it decreased VLDL levels by 42% and increased the rate of glucose clearance by 64% compared to naringenin alone. These effects correlated with increased expression of the PPAR co-activator, PGC1α in both liver and skeletal muscle. Histology and blood chemistry analysis indicated this route of administration was not associated with damage to the intestine, kidney, or liver. These results suggest that the complexation of naringenin with HPβCD is a viable option for the oral delivery of naringenin as a therapeutic entity with applications in the treatment of dyslipidemia, diabetes, and HCV infection. |
| format | Article |
| id | doaj-art-4e0d6087270240e9b94d7fe01ee55dc2 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2011-04-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-4e0d6087270240e9b94d7fe01ee55dc22025-08-20T03:10:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-04-0164e1803310.1371/journal.pone.0018033Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected].Maria ShulmanMerav CohenAlejandro Soto-GutierrezHiroshi YagiHongyun WangJonathan GoldwasserCarolyn W Lee-ParsonsOfra Benny-RatsabyMartin L YarmushYaakov NahmiasThe abundant flavonoid aglycone, naringenin, which is responsible for the bitter taste in grapefruits, has been shown to possess hypolipidemic and anti-inflammatory effects both in vitro and in vivo. Recently, our group demonstrated that naringenin inhibits hepatitis C virus (HCV) production, while others demonstrated its potential in the treatment of hyperlipidemia and diabetes. However, naringenin suffers from low oral bioavailability critically limiting its clinical potential. In this study, we demonstrate that the solubility of naringenin is enhanced by complexation with β-cyclodextrin, an FDA approved excipient. Hydroxypropoyl-β-cyclodextrin (HPβCD), specifically, increased the solubility of naringenin by over 400-fold, and its transport across a Caco-2 model of the gut epithelium by 11-fold. Complexation of naringenin with HPβCD increased its plasma concentrations when fed to rats, with AUC values increasing by 7.4-fold and C(max) increasing 14.6-fold. Moreover, when the complex was administered just prior to a meal it decreased VLDL levels by 42% and increased the rate of glucose clearance by 64% compared to naringenin alone. These effects correlated with increased expression of the PPAR co-activator, PGC1α in both liver and skeletal muscle. Histology and blood chemistry analysis indicated this route of administration was not associated with damage to the intestine, kidney, or liver. These results suggest that the complexation of naringenin with HPβCD is a viable option for the oral delivery of naringenin as a therapeutic entity with applications in the treatment of dyslipidemia, diabetes, and HCV infection.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0018033&type=printable |
| spellingShingle | Maria Shulman Merav Cohen Alejandro Soto-Gutierrez Hiroshi Yagi Hongyun Wang Jonathan Goldwasser Carolyn W Lee-Parsons Ofra Benny-Ratsaby Martin L Yarmush Yaakov Nahmias Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected]. PLoS ONE |
| title | Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected]. |
| title_full | Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected]. |
| title_fullStr | Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected]. |
| title_full_unstemmed | Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected]. |
| title_short | Enhancement of naringenin bioavailability by complexation with hydroxypropyl-β-cyclodextrin. [corrected]. |
| title_sort | enhancement of naringenin bioavailability by complexation with hydroxypropyl β cyclodextrin corrected |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0018033&type=printable |
| work_keys_str_mv | AT mariashulman enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT meravcohen enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT alejandrosotogutierrez enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT hiroshiyagi enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT hongyunwang enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT jonathangoldwasser enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT carolynwleeparsons enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT ofrabennyratsaby enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT martinlyarmush enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected AT yaakovnahmias enhancementofnaringeninbioavailabilitybycomplexationwithhydroxypropylbcyclodextrincorrected |